Protective effects of a PPAR-δ agonist and a non-erythropoietic peptide derivative of erythropoietin against the diet-induced development of skeletal muscle insulin resistance and inflammation in mice


1Dept. of Drug Science and Technology, University of Turin, Turin, Italy
2Dept. of Clinical and Biological Sciences, University of Turin, Turin, Italy
3Dept. of Biotechnology and Sciences for the Health, University of Turin, Italy
4ININCA-CONICET, Buenos Aires, Argentina
5Dept. of Molecular Medicine University of Pavia, Italy
6Division of Endocrinology, Diabetology and Metabolism, Dept. of Medical Sciences, University of Turin, Italy
7Queen Mary University of London, Centre for Translational Medicine and Therapeutics, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, London, UK

Here we report our recent findings on the testing of innovative pharmacological approaches dealing with the molecular modulation of the chronic inflammation involved in the development of metabolic disorders (metaflammation) [1], in in vivo models of obesity associated with type-2 diabetes (diabesity). We focused on skeletal muscles, which account for almost 80% of the insulin-stimulated glucose uptake, thus, exerting a key role in regulating whole body glucose homeostasis.

As drug targets, we investigated Peroxisome Proliferator Activated Receptor (PPAR)-δ, and the heterocomplex between the Erythropoietin Receptor (EpoR) and the β-common Receptor (βcR), which mediates the tissue-protective effects of Erythropoietin (EPO).

Male mice were chronically fed a diet enriched in fats (Protocol 1, 45% High Fat diet, HF), or in sugars (Protocol 2, 15% High-Fructose Corn Syrup, HFCS), or in both sugars and fats (Protocol 3, 40% High Fat and 30% High Sucrose diet, HFHS).

A subgroup of HFCS mice (Protocol 2) was treated with a highly potent and selective PPAR-δ agonist, GW0742 (1 mg/kg/day for 16 weeks). A subgroup of HFHS mice (Protocol 3) received an EPO derivative devoid of haematopoietic effects, which selectively binds the EpoR–βcR heterocomplex, the pyroglutamate Helix B Surface Peptide (pHBSP, 30 μg/kg s.c. for 11 weeks). Both the drugs have been previously tested in our lab at the doses here reported in models of cardiovascular diseases [2, 3].

Our results show that the three different dietary manipulations caused a significant increase in body weight, dyslipidemia and hyperinsulinemia and evoked insulin resistance due to impaired insulin signaling within the skeletal muscle. The effects of dietary manipulation were comparatively evaluated in two different muscles characterized by high dependence on either oxidative or glycolytic metabolism, the soleus and the tibialis, respectively. Results showed that the soleus stores more triglycerides (TG) than the tibialis in control animals, while the TG content of the two muscles was comparable in mice exposed to the HF or HFHS diets. Moreover, the chronic exposure to high caloric diets evoked a massive skeletal muscle accumulation of advanced glycation end-products (AGEs) that was preferential for the lipid-accumulating cells and increased expression of the lipogenic pathway SCAP/SREBP.

When drugs effects were evaluated, either GW0742 or pHBSP attenuated the systemic metabolic anomalies caused by diet. To elucidate the potential mechanisms underlying their beneficial effects, we proved that GW0742 induced PPAR-δ upregulation in skeletal muscle and this effect was accompanied by marked inhibition of nuclear factor-kB activation and muscular expression of inducible-nitric-oxide-synthase, intercellular-adhesion-molecule-1 and the myokine Fibroblast Growth Factor-21 (FGF-21). Similarly, diet-induced overproduction of IL-6 and FGF-21 were attenuated by pHBSP and, most importantly, pHBSP markedly enhanced mitochondrial biogenesis. Besides, both GW0742 and pHBSP stimulate glucose transport in skeletal muscle by increasing the translocation of the sugar transporter GLUT-4 to the plasma membrane.

Overall, the models of dietary manipulation here described can be proposed as suitable experimental tools for studying 'diabesity' and its potential pharmacological modulation. Our results demonstrated that activation of either PPAR-δ or EpoR/βcR protects the skeletal muscle against the diet-induced metabolic abnormalities by affecting multiple levels of the insulin and inflammatory cascades. These local protective effects may support their potential role as innovative pharmacological tools in metabolic disorders.